In terms of potential therapeutic strategies for cardiovascular diseases, inhibition of hsa-ABLIM1_0001, hsa-RNF13_0004, and hsa-KIF1B_0001, or overexpression of hsa-MYOM1_0001, hsa-AC096949_0001, and hsa-PDLIM5_0001, may be promising in promoting cardiomyocyte cell cycle and heart regeneration. This evidence concerns the gene PDLIM5 and cardiovascular disorder.